IMUNON, Inc. announced additional clinical data from ongoing analyses of results from the Company?s Phase 2 OVATION 2 Study of IMNN-001, its investigational interleukin-12 (IL-12) immunotherapy for the treatment of advanced ovarian cancer based on its proprietary TheraPlas technology. The updated results, based on an additional seven months of patient monitoring, show the hazard ratio decreased from 0.74 to 0.69, with an increase in median overall survival from 11.1 to 13 months following treatment with IMNN-001 plus standard-of-care neoadjuvant and adjuvant chemotherapy versus SoC alone. More than one-third of patients in the trial survived more than 36 months from the point of study enrollment, with 62% of those surviving patients from the IMNN-001 treatment arm and 38% from the SoC arm.

Over 10% of trial participants have reached 48 months or beyond. The OVATION 2 Study included a total of 112 patients with newly diagnosed advanced ovarian cancer (intent-to-treat population). Study participants were randomized 1:1 to evaluate the safety and efficacy of IMNN-001 (100 mg/m2 administered intraperitoneally weekly) plus NACT of paclitaxel and carboplatin compared to SoC NACT alone.

Initial results from the OVATION 2 Study were reported in July 2024 and results were recently presented in a late-breaking session at the Society for Immunotherapy of Cancer 39th Annual Meeting in November 2024.